Prelude Therapeutics (PRLD)
(Delayed Data from NSDQ)
$5.16 USD
-1.04 (-16.77%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $5.16 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Prelude Therapeutics Incorporated falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 233 | 202 | 291 | 218 | 19 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 3 | 4 | 3 | 1 |
Total Current Assets | 236 | 204 | 295 | 221 | 20 |
Net Property & Equipment | 7 | 5 | 4 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 4 | 9 | 4 | 0 | 0 |
Total Assets | 278 | 221 | 305 | 224 | 22 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 7 | 8 | 4 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 16 | 13 | 10 | 7 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 22 | 22 | 19 | 11 | 5 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3 | 3 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 41 | 25 | 19 | 11 | 5 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 66 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 693 | 532 | 506 | 320 | 1 |
Retained Earnings | -456 | -335 | -219 | -107 | -51 |
Other Equity | 0 | -2 | -1 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 237 | 195 | 286 | 212 | 17 |
Total Liabilities & Shareholder's Equity | 278 | 221 | 305 | 224 | 22 |
Total Common Equity | 237 | 195 | 286 | 212 | -49 |
Shares Outstanding | 54.80 | 47.80 | 47.20 | 43.70 | NA |
Book Value Per Share | 4.33 | 4.09 | 6.06 | 4.86 | 0.00 |
Fiscal Year End for Prelude Therapeutics Incorporated falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 202 | 233 | 231 | 255 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 3 | 3 | 4 | 5 |
Total Current Assets | NA | 205 | 236 | 235 | 260 |
Net Property & Equipment | NA | 7 | 7 | 7 | 6 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 4 | 4 | 17 | 13 |
Total Assets | NA | 247 | 278 | 259 | 281 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 5 | 5 | 5 | 6 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 10 | 16 | 11 | 9 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 18 | 22 | 17 | 15 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 3 | 3 | 3 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 36 | 41 | 20 | 19 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 699 | 693 | 662 | 655 |
Retained Earnings | NA | -488 | -456 | -423 | -393 |
Other Equity | NA | 0 | 0 | -1 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 211 | 237 | 238 | 262 |
Total Liabilities & Shareholder's Equity | NA | 247 | 278 | 259 | 281 |
Total Common Equity | 0 | 211 | 237 | 238 | 262 |
Shares Outstanding | 54.90 | 54.90 | 54.80 | 54.80 | 47.90 |
Book Value Per Share | 0.00 | 3.84 | 4.33 | 4.35 | 5.47 |